Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Glostrup University Hospital, Copenhagen
ClinicalTrials.gov Identifier:
NCT00673751
First received: May 5, 2008
Last updated: May 6, 2008
Last verified: May 2008
  Purpose

The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome


Condition Intervention
Short Bowel Syndrome
Drug: GLP-2
Drug: Placebo

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome

Resource links provided by NLM:


Further study details as provided by Glostrup University Hospital, Copenhagen:

Estimated Enrollment: 8
Arms Assigned Interventions
Placebo Comparator: 2
subcutaneous isotonic saline
Drug: Placebo
Active Comparator: 1
subcutaneous GLP-2
Drug: GLP-2
450 nmol subcutaneous

Detailed Description:

previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinical diagnose of short bowel syndrome 4 month of stable fase

Exclusion Criteria:

  • activity in IBD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00673751

Locations
Denmark
Glostrup University Hospital
Glostrup, Region Hovedstaden, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
  More Information

No publications provided

Responsible Party: Lasse Bremholm, Dept. of gastroenterology, Glostrup Hospital, University of Copenhagen
ClinicalTrials.gov Identifier: NCT00673751     History of Changes
Other Study ID Numbers: H-A-2008-032
Study First Received: May 5, 2008
Last Updated: May 6, 2008
Health Authority: Denmark: National Board of Health

Keywords provided by Glostrup University Hospital, Copenhagen:
mesenteric blood flow
GLP-2
short bowel syndrome
Glucagon-Like Peptide 2

Additional relevant MeSH terms:
Short Bowel Syndrome
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Postoperative Complications
Pathologic Processes

ClinicalTrials.gov processed this record on August 28, 2014